Skip to main content
Top
Published in: Hepatology International 2/2024

Open Access 21-01-2024 | Hepatitis C | Original Article

An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan

Authors: Ming-Lung Yu, Chi‐Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Chung-Feng Huang, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang, Yi-Hsiang Huang, Lee-Won Chong, Chien-Lin Chen, Chi-Chieh Yang, Chao-Hung Hung, Sheng‐Shun Yang, Pin-Nan Cheng, Tsai-Yuan Hsieh, Jui-Ting Hu, Wen-Chih Wu, Chien-Yu Cheng, Guei-Ying Chen, Guo-Xiong Zhou, Wei-Lun Tsai, Chien-Neng Kao, Chih-Lang Lin, Chia-Chi Wang, Ta-Ya Lin, Chih‐Lin Lin, Wei-Wen Su, Tzong-Hsi Lee, Te-Sheng Chang, Chun-Jen Liu, Chia-Yen Dai, Chi-Yi Chen, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Cheng-Yuan Peng

Published in: Hepatology International | Issue 2/2024

Login to get access

Abstract

Background

Both European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) guidelines recommend simplified hepatitis C virus (HCV) treatment with pan-genotypic sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for eligible patients. This observational study used real-world data to assess these regimens’ safety in eligible patients and develop an algorithm to identify patients suitable for simplified treatment by non-specialists.

Methods

7,677 HCV-infected patients from Taiwan Hepatitis C Registry (TACR) who received at least one dose of sofosbuvir/velpatasvir or glecaprevir/pibrentasvir, and fulfilled the EASL/AASLD-IDSA criteria for simplified treatment were analyzed. Multivariate analysis was conducted on patient characteristics and safety data.

Results

Overall, 92.8% (7,128/7,677) of patients achieved sustained virological response and only 1.9% (146/7,677) experienced Grades 2–4 laboratory abnormalities in key liver function parameters (alanine aminotransferase, aspartate aminotransferase, and total bilirubin), with only 18 patients (0.23%) experiencing Grades 3–4 abnormalities. Age > 70 years old, presence of hepatocellular carcinoma, total bilirubin > 1.2 mg/dL, estimated glomerular filtration rate < 60 mL/min/1.73 m2, and Fibrosis-4 > 3.25 were associated with higher risks of Grades 2–4 abnormalities. Patients with any of these had an odds of 4.53 times than that of those without in developing Grades 2–4 abnormalities (p < 0.01).

Conclusions

Real-world data from Taiwan confirmed that simplified HCV treatment for eligible patients with pan-genotypic regimens is effective and well tolerated. The TACR algorithm, developed based on this study’s results, can further identify patients who can be safely managed by non-specialist care.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Dieterich DT. A simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol. 2019;15(5 Suppl 3):1–12 Dieterich DT. A simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol. 2019;15(5 Suppl 3):1–12
2.
go back to reference The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396–415CrossRef The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396–415CrossRef
3.
go back to reference World Health Organization. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations, 2022 World Health Organization. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations, 2022
4.
go back to reference Castro R, et al. Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis. PLoS ONE. 2020;15(2): e0229143CrossRefPubMedPubMedCentral Castro R, et al. Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis. PLoS ONE. 2020;15(2): e0229143CrossRefPubMedPubMedCentral
5.
go back to reference Oru E, et al. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Glob Health. 2021;9(4):e431–445CrossRefPubMedPubMedCentral Oru E, et al. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Glob Health. 2021;9(4):e431–445CrossRefPubMedPubMedCentral
6.
go back to reference Majethia S, et al. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C. J Manag Care Spec Pharm. 2022;28(1):48–57PubMed Majethia S, et al. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C. J Manag Care Spec Pharm. 2022;28(1):48–57PubMed
7.
go back to reference Klein MB. Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. Lancet Gastroenterol Hepatol. 2022;7(4):277–279CrossRefPubMedPubMedCentral Klein MB. Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. Lancet Gastroenterol Hepatol. 2022;7(4):277–279CrossRefPubMedPubMedCentral
8.
go back to reference American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C, 2021 American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C, 2021
9.
go back to reference European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series(☆). J Hepatol. 2020;73(5):1170–1218CrossRef European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series(☆). J Hepatol. 2020;73(5):1170–1218CrossRef
10.
go back to reference Falade-Nwulia O, Sulkowski MS. Hepatitis C virus treatment: simplifying the simple and optimizing the difficult. J Infect Dis. 2020;222(Suppl 9):S745-757CrossRefPubMedPubMedCentral Falade-Nwulia O, Sulkowski MS. Hepatitis C virus treatment: simplifying the simple and optimizing the difficult. J Infect Dis. 2020;222(Suppl 9):S745-757CrossRefPubMedPubMedCentral
11.
go back to reference Cheng PN, et al. Sofosbuvir/velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan. Infect Dis Ther. 2022;11(1):485–500CrossRefPubMed Cheng PN, et al. Sofosbuvir/velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan. Infect Dis Ther. 2022;11(1):485–500CrossRefPubMed
13.
go back to reference Yu ML, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: A nationwide survey in Taiwan. Medicine (Baltimore). 2015;94(13): e690CrossRefPubMedPubMedCentral Yu ML, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: A nationwide survey in Taiwan. Medicine (Baltimore). 2015;94(13): e690CrossRefPubMedPubMedCentral
15.
go back to reference Haridy J, et al. Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation. Intern Med J. 2021;51(11):1927–1934CrossRefPubMed Haridy J, et al. Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation. Intern Med J. 2021;51(11):1927–1934CrossRefPubMed
16.
go back to reference Chen CY, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021;41(6):1265–1277CrossRefPubMedPubMedCentral Chen CY, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021;41(6):1265–1277CrossRefPubMedPubMedCentral
17.
go back to reference Yu ML, et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (I) general population. J Formos Med Assoc. 2020;119(6):1019–1040CrossRefPubMed Yu ML, et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (I) general population. J Formos Med Assoc. 2020;119(6):1019–1040CrossRefPubMed
18.
go back to reference Yu ML, et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. J Formos Med Assoc. 2020;119(7):1135–1157CrossRefPubMed Yu ML, et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. J Formos Med Assoc. 2020;119(7):1135–1157CrossRefPubMed
20.
go back to reference Huang C-F, et al. Extrahepatic malignancy among patients with chronic hepatitis C after antiviral therapy: A real-world nationwide study on Taiwanese chronic hepatitis C cohort (T-COACH). Am J Gastroenterol. 2020;115(8):1226–1235CrossRefPubMed Huang C-F, et al. Extrahepatic malignancy among patients with chronic hepatitis C after antiviral therapy: A real-world nationwide study on Taiwanese chronic hepatitis C cohort (T-COACH). Am J Gastroenterol. 2020;115(8):1226–1235CrossRefPubMed
21.
go back to reference Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470CrossRefPubMed Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470CrossRefPubMed
22.
go back to reference Gane E, et al. Safety and pharmacokinetics of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infections and compensated liver disease. Clin Infect Dis. 2019;69(10):1657–1664CrossRefPubMedPubMedCentral Gane E, et al. Safety and pharmacokinetics of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infections and compensated liver disease. Clin Infect Dis. 2019;69(10):1657–1664CrossRefPubMedPubMedCentral
24.
go back to reference Huang C-F, et al. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: A large cohort study from the nationwide HCV registry program (TACR). Clin Gastroenterol Hepatol. 2022;20(5):1151-1162.e6CrossRefPubMed Huang C-F, et al. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: A large cohort study from the nationwide HCV registry program (TACR). Clin Gastroenterol Hepatol. 2022;20(5):1151-1162.e6CrossRefPubMed
25.
go back to reference Ogawa E, et al. Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: A practice implication. Clin Infect Dis. 2020;71(11):2840–2848CrossRefPubMed Ogawa E, et al. Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: A practice implication. Clin Infect Dis. 2020;71(11):2840–2848CrossRefPubMed
26.
go back to reference Yeh M-L, et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol. 2020;73(1):62–71CrossRefPubMed Yeh M-L, et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol. 2020;73(1):62–71CrossRefPubMed
28.
go back to reference Wan Z, et al. Reinfection rate of hepatitis C in HIV-1 positive men who have sex with men: A systematic review and meta-analysis. Front Public Health. 2022;10 Wan Z, et al. Reinfection rate of hepatitis C in HIV-1 positive men who have sex with men: A systematic review and meta-analysis. Front Public Health. 2022;10
29.
30.
go back to reference Ioannou GN, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264-1278.e4CrossRefPubMed Ioannou GN, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264-1278.e4CrossRefPubMed
31.
go back to reference Simon MA, Rojo O, Ryan P. Patients’ preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection. Rev Esp Sanid Penit. 2021;23(2):67–75CrossRefPubMedPubMedCentral Simon MA, Rojo O, Ryan P. Patients’ preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection. Rev Esp Sanid Penit. 2021;23(2):67–75CrossRefPubMedPubMedCentral
32.
go back to reference Welzel TM, et al. Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections. Adv Ther. 2019;36(9):2475–2486CrossRefPubMedPubMedCentral Welzel TM, et al. Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections. Adv Ther. 2019;36(9):2475–2486CrossRefPubMedPubMedCentral
33.
go back to reference Yu ML, et al. TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes. J Formos Med Assoc. 2023;122(3):202–220CrossRefPubMed Yu ML, et al. TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes. J Formos Med Assoc. 2023;122(3):202–220CrossRefPubMed
Metadata
Title
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
Authors
Ming-Lung Yu
Chi‐Ming Tai
Lein-Ray Mo
Hsing-Tao Kuo
Chung-Feng Huang
Kuo-Chih Tseng
Ching-Chu Lo
Ming-Jong Bair
Szu-Jen Wang
Jee-Fu Huang
Ming-Lun Yeh
Chun-Ting Chen
Ming-Chang Tsai
Chien-Wei Huang
Pei-Lun Lee
Tzeng-Hue Yang
Yi-Hsiang Huang
Lee-Won Chong
Chien-Lin Chen
Chi-Chieh Yang
Chao-Hung Hung
Sheng‐Shun Yang
Pin-Nan Cheng
Tsai-Yuan Hsieh
Jui-Ting Hu
Wen-Chih Wu
Chien-Yu Cheng
Guei-Ying Chen
Guo-Xiong Zhou
Wei-Lun Tsai
Chien-Neng Kao
Chih-Lang Lin
Chia-Chi Wang
Ta-Ya Lin
Chih‐Lin Lin
Wei-Wen Su
Tzong-Hsi Lee
Te-Sheng Chang
Chun-Jen Liu
Chia-Yen Dai
Chi-Yi Chen
Jia-Horng Kao
Han-Chieh Lin
Wan-Long Chuang
Cheng-Yuan Peng
Publication date
21-01-2024
Publisher
Springer India
Published in
Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10609-7

Other articles of this Issue 2/2024

Hepatology International 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare